Gyre Therapeutics, Inc. Increase (Decrease) in Accounts and Other Receivables
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Accounts and Other Receivables of -$1.62 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2023-10-26
- Gyre Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2022-09-30 was $0.00.
- Gyre Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2022-06-30 was -$564.00K.
- Gyre Therapeutics, Inc. increase (decrease) in accounts and other receivables for the quarter ending 2022-03-31 was -$1.05M.
- Gyre Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2022 was -$1.62M.
- Gyre Therapeutics, Inc. increase (decrease) in accounts and other receivables for fiscal 2021 was -$1.50M.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | -$564.00K derived: sum of 3 quarters · filed 2023-10-26 | -$1.62M 10-K · filed 2023-03-30 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | -$564.00K derived: sum of 2 quarters · filed 2023-10-26 | -$1.62M 10-Q · filed 2023-10-26 | -$914.00K derived: sum of 4 quarters · filed 2023-10-26 |
| 2022-06-30 | -$564.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$1.62M 10-Q · filed 2023-08-14 | -$914.00K derived: sum of 3 quarters · filed 2023-08-14 | -$1.77M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$1.05M 10-Q · filed 2023-05-15 | -$350.00K derived: sum of 2 quarters · filed 2023-05-15 | -$1.21M derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $704.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$153.00K derived: sum of 2 quarters · filed 2023-03-30 | -$1.50M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$857.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$2.20M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$1.34M 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |